Table 1.
Patient characteristics.
Fig 1.
MiRNA-107 expression levels in HCC tissue represent a prognostic marker.
Kmplot was used to analyze the prognostic value of miR-107 in HCC in NGS data from TCGA, GEO, and EGA (n = 372 patients). Patients were automatically split by Kmplot in two groups with low (n = 214) and high (n = 158) levels for miR-107 expression (expression range, 70–989, cut off expression: 270,22). Overall survival of HCC patients with high tumoral miR-107 expression levels is significantly higher compared to patients with low miR-107 expression levels (HR 0.69, 95% CI 0.48–0.99, p = 0.41).
Fig 2.
MiRNA-107 levels are upregulated in HCC patients.
(A) Circulating miR-107 levels are significantly higher in HCC patients compared to healthy controls. (B) Circulating miR-107 levels show an AUC value of 0.679 regarding the discrimination between HCC and healthy controls.
Table 2.
Serum levels of various laboratory markers.
Fig 3.
Circulating miR-107 levels in different HCC subgroups.
Serum miR-107 levels do not significantly differ between patients with different liver disease etiology (A), tumor stage (B), tumor grading (C), surgical resection status (D) as well as between male and female patients (E) or patients with an unimpaired/impaired ECOG performance status (F). MiR-107 serum levels do not correlate with the size of HCC (G).
Table 3.
Correlation analysis between miR-107 expression levels and various laboratory markers.
Fig 4.
Serum levels of circulating miR-107 are unsuitable to predict outcome in early-stage HCC patients.
(A) HCC patients with miR-107 serum levels above or below the 50th percentile (3.12) have a comparable overall survival. (B) HCC patients with miR-107 serum levels above the ideal prognostic cut-off value (9.82) show a non-significant trend (p = 0.119) towards an impaired survival.